Target intelligence / Profile preview

Ras-related protein Rab-37 (RAB37)

Target
RAB37
Molecular classification
Small GTPase, Rab family protein, Regulatory protein of intracellular vesicle trafficking, Member of the RAS oncogene superfamily
01

Overview

Ras-related protein Rab-37 (RAB37) is a small GTPase belonging to the Rab family within the RAS oncogene superfamily. It regulates intracellular vesicle trafficking and exocytosis, playing a critical role in processes such as autophagy, secretion of anti-tumor factors (like TIMP1 and thrombospondin-1), and insulin granule release. In various cancers, RAB37 functions predominantly as a metastasis suppressor by mediating the exocytosis of cargo proteins that inhibit migration, invasion, and neovasculature formation, thus modulating the tumor microenvironment. Its expression is often reduced via hypermethylation in tumors, leading to increased metastasis and poorer prognosis. In specific contexts, such as tumor-associated macrophages, RAB37 may exert protumorigenic effects by mediating secretion of immunomodulatory cytokines. RAB37 is not currently a direct drug target, but its pathway is subject to regulation by posttranslational modifications, including phosphorylation by protein kinase C alpha, which abrogates its tumor suppressive exocytic functions[1][2][3][4][5][7].

Other names
Rab37RAB37member RAS oncogene family
02

Mechanism of action

Not directly drug-modulated; protein activity regulated by post-translational modifications such as phosphorylation (notably by PKCα), methylation, and epigenetic mechanisms[1][2][3][4]

03

Biological functions

Intracellular vesicle traffickingExocytosis of secreted glycoproteinsAutophagosome biogenesis/autophagySecretion of regulatory proteins (e.g., TIMP1, thrombospondin-1)Insulin-containing secretory granule docking and exocytosis in pancreatic β-cellsRegulation of tumor microenvironment signaling
04

Disease associations

Cancer (metastasis suppressor in some tumors, possible tumor promoter in tumor-associated macrophages)Tumor angiogenesis inhibitionPrognostic biomarker in various carcinomas (lung cancer, esophageal cancer, others)
05

Safety considerations

No direct therapeutic targeting by drugs established; safety profile not determined. Mechanistic targeting could risk broad disruption of cellular trafficking, homeostasis, and cross-talk in immune/cancer pathways[2][3].
06

Biomarkers

Loss or reduced expression associated with metastasis and poor prognosis in non-small cell lung cancer and other epithelial cancers[1][2][4]Methylation status may serve as a prognostic biomarker in solid tumors[2]

Beyond the preview

Go deeper on Ras-related protein Rab-37 (RAB37).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras-related protein Rab-37 (RAB37).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call